

Patient ID SA00119501	Patient Name TESTING, BILLING	Birth Date 1996-11-11	Gender M	Age 22
Order Number SA00119501	Client Order Number SA00119501	Ordering Physician CLIENT, CLIENT	Report Notes	
Account Information C7999998 Test Client		Collected 10 Apr 2019 01:00		

PD-L1 (SP263) SemiQuant IHC, Manual

Case Number CR-19-256

Interpretation

MCR

Lung, lower left lobe, specimen for PD-L1 immunohistochemistry studies (clone SP263, Ventana Medical Systems Inc, Tucson, AZ) (BS-19-4-M9):

25% tumor cells are positive for PD-L1 (membranous positivity).

PD-L1-positive immune cells cover less than 5% of tumor area.

Interpretation: Pre-clinical studies suggest that positive PD-L1 immunohistochemistry in tumor cells may predict tumor response to therapy with immune checkpoint inhibitors. This result should not be used as the sole factor in determining treatment, as other factors (for example, tumor mutation burden, and microsatellite instability) have been also studied as predictive markers.

Fixation: This test has been validated for non-decalcified paraffin embedded tissue specimens fixed in 10% neutral buffered formalin. This assay has not been validated on tissues subjected to the decalcification process and/or use of alternative fixatives for bone/bone marrow specimens or cell blocks.

Material Received

MCR

Report electronically signed by

MCR

A. BS-19-4: Lung, lower left lobe
2 unstained slides

CALEB HALL

Disclaimer

MCR

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

Received: 11 Apr 2019 08:36

Reported: 11 Apr 2019 09:42

Performing Site Legend

Code	Laboratory	Address	Lab Director	CLIA Certificate
MCR	Mayo Clinic Laboratories - Rochester Main Campus	200 First Street SW, Rochester, MN 55905	William G. Morice M.D. Ph.D	24D0404292